Compare CPRI & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRI | NVAX |
|---|---|---|
| Founded | 1981 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2011 | 1996 |
| Metric | CPRI | NVAX |
|---|---|---|
| Price | $15.88 | $9.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $22.22 | $14.22 |
| AVG Volume (30 Days) | 2.9M | ★ 8.1M |
| Earning Date | 10-30-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 111.40 | ★ 309.76 |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $3,474,000,000.00 | $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | $27.29 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $12.40 | $6.20 |
| 52 Week High | $28.27 | $13.39 |
| Indicator | CPRI | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 40.84 |
| Support Level | $14.99 | $7.93 |
| Resistance Level | $16.05 | $10.26 |
| Average True Range (ATR) | 0.66 | 1.10 |
| MACD | 0.10 | -0.32 |
| Stochastic Oscillator | 64.76 | 5.28 |
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.